Biology subjects

Lefranc, B.

Publications and source records attributed to Lefranc, B..

7 recordsLinked to original sources

bioRxiv2026

Functional characterization of the 26RFa/orexin neurons of the lateral hypothalamic area reveals their key role in the control of glucose homeostasis

Defining the nature and molecular mechanisms of the neurocircuitry controlling glucose homeostasis is crucial in understanding how alterations in these pathways promote the development of obesity and type 2 diabetes. Here, we functionally characterize a population of lateral hypothalamic neurons co-expressing the anti-hyperglycemic neuropeptides 26RFa and orexin. Using complementary chemogenetic, pharmacological and genetic approaches, including mice deficient for 26RFa, orexin or both neuropeptides, we investigated the respective contribution of each signaling system to glucose homeostasis. We found that lateral hypothalamic 26RFa neurons extensively co-express orexin, defining a distinct peptidergic population with convergent anti-hyperglycemic properties. Unexpectedly, chemogenetic activation of these neurons potentiated glucose-induced hyperglycemia despite the anti-hyperglycemic properties of both neuropeptides. To understand this paradox, we examined the transcriptional responses of the 26RFa and orexin peptidergic systems and found that neuronal activation was associated with coordinated, glycemic state-dependent downregulation of both signaling systems. Furthermore, genetic loss-of-function approaches revealed distinct contributions of the two neuropeptidergic systems, with orexin signaling mediating most of the metabolic consequences of neuronal activation, whereas 26RFa signaling is required for the dynamic regulation of orexin expression. Finally, our findings provide new insights into the functional organization of lateral hypothalamic 26RFa/orexin neurons and advance our understanding of how coordinated neuropeptidergic signaling contributes to systemic glucose homeostasis.

neuroscience↗

bioRxiv2026

The stereochemical mechanism of the B12-dependent radical SAM glutamine methyltransferase (QCMT): Novel insights and unprecedented post-translational modifications

Methyl-coenzyme M reductase (MCR) is a crucial enzyme for methanogenesis and harbors several unusual post-translational modifications. Recent studies have identified glutamine C-methyltransferase (QCMT), as a B12-dependent radical SAM enzyme responsible for methylating a glutamine residue within the MCR active site. B12-dependent radical SAM enzymes have the remarkable ability to alkylate unactivated Csp2- and Csp3-atoms in a stereoselective manner. However, the factors influencing the stereo-selectivity and catalytic properties of this emerging superfamily of enzymes remain poorly understood. In this study, we report the mechanistic, structural, and biochemical investigation of several QCMTs. Our findings reveal significant differences among them, notably in their ability to bind cobalamin. In addition, our data support that C H-atom abstraction and methyl transfer are not concerted but rather independent processes that require motion within the enzymes active site. We also demonstrate that QCMT can catalyze novel reactions, including the formation of unnatural C-methylated residues, peptide epimerization, reversible H-atom abstraction, and the direct conversion of glycine into O_SCPLOWDC_SCPLOW-alanine. Overall, our data are consistent with QCMT being a unique and versatile biocatalyst allowing for the installation of unnatural post-translational modifications and provide a structural and biochemical rationale for the control of the stereochemistry by B12-dependent radical SAM enzymes.

biochemistry↗

bioRxiv2024

Staphylococcus warneri dampens SUMOylation and promotes intestinal inflammation

Gut bacteria play key roles in intestinal physiology, via the secretion of diversified bacterial effectors. Many of these effectors remodel the host proteome, either by altering transcription or by regulating protein post-translational modifications. SUMOylation, a ubiquitin-like post-translational modification playing key roles in intestinal physiology, is a target of gut bacteria. Mutualistic gut bacteria can promote SUMOylation, via the production of short- or branched-chain fatty acids (SCFA/BCFA). In contrast, several pathogenic bacteria were shown to dampen SUMOylation in order to promote infection. Here, we challenge this dichotomic vision by showing that Staphylococcus warneri, a non-pathogenic bacterium of the human gut microbiota, decreases SUMOylation in intestinal cells. We identified that Warnericin RK, a hemolytic toxin secreted by S. warneri, targets key components of the host SUMOylation machinery, leading to the loss of SUMO-conjugated proteins. We further demonstrate that the dampening of SUMOylation triggered by Warnericin RK promotes inflammation, and, more particularly, TNF-dependent intestinal inflammatory responses. Together, these results highlight the diversity of mechanisms used by non-pathogenic bacteria from the gut microbiota to manipulate host SUMOylation. They further highlight that changes in gut microbiota composition may impact intestinal inflammation, by changing the equilibrium between bacterial effectors promoting or dampening SUMOylation.

microbiology↗

bioRxiv2022

A novel computational method for head-to-tail peptide cyclization: application to urotensin II

Backbone head-to-tail cyclization is one effective strategy to stabilize the conformation of bioactive peptides, preventing enzymatic degradation and improving their bioavailibility. However, very little is known about the requirements to rationally design linkers for the cyclization of linear peptides. Recently, we have shown that large scale data-mining of protein structures can lead to the precise identification of protein loop conformations. Here, we transpose this approach to head-to-tail peptide cyclization. We first show that given a linker sequence and the conformation of the linear peptide, it is possible to accurately predict the cyclized peptide conformation improving by over 1 [A] over pre-existing protocols. Secondly, and more importantly, we show that it is possible to elaborate on the information inferred from protein structures to propose effective candidate linker sequences constrained by length and amino acid composition. As experimental validation, we first apply our approach to design linkers for the head-to-tail cyclizations of a peptide derived from Nrf2. The designed cyclized peptide shows a 26-fold increase in binding affinity. We then consider urotensin II, a cyclic peptide already stabilized by a disulfide bond, that exerts a broad array of biological activities. The designed head-to-tail cyclized peptide, the first synthesized bicyclic 14-residue long urotensin II analogue shows an excellent retention of in vitro activity. Overall, we propose the first framework for the rational peptide head-to-tail cyclization and reveal its potential for cyclic peptide-based drug design.

bioinformatics↗

bioRxiv2021

Identification of a discrete neuronal circuit that relays insulin signaling into the brain to regulate glucose homeostasis

26RFa (QRFP) is a biologically active peptide that regulates glucose homeostasis by acting as an incretin and by increasing insulin sensitivity at the periphery. 26RFa is also produced by a neuronal population localized in the hypothalamus. In the present study, we have investigated whether the 26RFa neurons may be involved in the hypothalamic regulation of glucose homeostasis. Our data indicate that 26RFa, i.c.v. injected, induces a robust antihyperglycemic effect associated with an increase of insulin production by the pancreatic islets. In addition, we found that insulin strongly stimulates 26RFa expression and secretion by the hypothalamus. RNAscope experiments revealed that neurons expressing 26RFa in the lateral hypothalamic area and the ventromedial hypothalamic nucleus also express the insulin receptor and that insulin induces the expression of 26RFa in these neurons. Concurrently, we show that the central antihyperglycemic effect of insulin is abolished in presence of a 26RFa receptor (GPR103) antagonist as well as in mice deficient for 26RFa. Finally, our data indicate that the hypothalamic 26RFa neurons are not involved in the central inhibitory effect of insulin on hepatic glucose production, but mediate the central effects of the hormone on its own peripheral production. To conclude, in the present study we have identified a novel actor of the hypothalamic regulation of glucose homeostasis, the 26RFa/GPR103 system and we provide the evidence that this neuronal peptidergic system is a key relay for the central regulation of glucose metabolism by insulin.

physiology↗

bioRxiv2020

The gliopeptide ODN, a ligand for the benzodiazepine site of GABAA receptors, boosts functional recovery after stroke

Following stroke, the survival of neurons and their ability to re-establish connections is critical to functional recovery. This is strongly influenced by the balance between neuronal excitation and inhibition. In the acute phase of experimental stroke, lethal hyperexcitability can be attenuated by positive allosteric modulation of GABAA receptors (GABAAR). Conversely, in the late phase, negative allosteric modulation of GABAAR can correct the sub-optimal excitability and improves both sensory and motor recovery. Here, we hypothesized that octadecaneuropeptide (ODN), an endogenous allosteric modulator of the GABAAR synthesized by astrocytes, influences the outcome of ischemic brain tissue and subsequent functional recovery. We show that ODN boosts the excitability of cortical neurons, which make it deleterious in the acute phase of stroke. However, if delivered after day 3, ODN is safe and improves motor recovery over the following month in two different paradigms of experimental stroke in mice. Furthermore, we bring evidence that during the sub-acute period after stroke, the repairing cortex can be treated with ODN by means of a single hydrogel deposit into the stroke cavity. SIGNIFICANCE STATEMENTStroke remains a devastating clinical challenge because there is no efficient therapy to either minimize neuronal death with neuroprotective drugs or to enhance spontaneous recovery with neurorepair drugs. Around the brain damage, the peri-infarct cortex can be viewed as a reservoir of plasticity. However, the potential of wiring new circuits in these areas is restrained by a chronic excess of GABAergic inhibition. Here we show that an astrocyte-derived peptide (ODN), can be used as a delayed treatment, to safely correct cortical excitability and facilitate sensorimotor recovery after stroke.

neuroscience↗

bioRxiv2019

Glucose homeostasis is impaired in mice deficient for the neuropeptide 26RFa (QRFP)

Introduction26RFa (QRFP) is a biologically active peptide that has been found to control feeding behaviour by stimulating food intake, and to regulate glucose homeostasis by acting as an incretin. The aim of the present study was thus to investigate the impact of 26RFa gene knockout on the regulation of energy and glucose metabolism. Research design and methods26RFa mutant mice were generated by homologous recombination, in which the entire coding region of prepro-26RFa was replaced by the iCre sequence. Energy and glucose metabolism was evaluated through measurement of complementary parameters. Morphological and physiological alterations of the pancreatic islets were also investigated. ResultsOur data do not reveal significant alteration of energy metabolism in the 26RFa-deficient mice except the occurrence of an increased basal metabolic rate. By contrast, 26RFa mutant mice exhibit an altered glycemic phenotype with an increased hyperglycemia after a glucose challenge associated with an impaired insulin production, and an elevated hepatic glucose production. 2D and 3D immunohistochemical experiments indicate that the insulin content of pancreatic {beta} cells is much lower in the 26RFa-/- mice as compared to the wild-type littermates. ConclusionDisruption of the 26RFa gene induces substantial alteration in the regulation of glucose homeostasis with, in particular, a deficit in insulin production by the pancreatic islets. These findings further support the notion that 26RFa is an important regulator of glucose homeostasis. Significance of this studyO_ST_ABSWhat is already known about this subject?C_ST_ABS26RFa is a biologically active peptide produced in abundance in the gut and the pancreas. 26RFa has been found to regulate glucose homeostasis by acting as an incretin and by increasing insulin sensitivity. What are the new findings?Disruption of the 26RFa gene induces substantial alteration in the regulation of glucose homeostasis with, in particular, a deficit in insulin production by the pancreatic islets, assessing therefore the notion that 26RFa is an important regulator of glucose homeostasis. How might these results change the focus of research or clinical practice?Identification of a novel actor in the regulation of glucose homeostasis is crucial to better understand the general control of glucose metabolism in physiological and pathophysiological conditions, and opens new fields of investigation to develop innovative drugs to treat diabetes mellitus.

physiology↗